AEDL
AEDL Tetrapeptide | Bronchial Bioregulator
DoseGear research brief
Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair.
Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
AEDL tetrapeptide attributed to Khavinson and St. Petersburg bioregulation research.
Experimental bronchopulmonary tissue regulation through proposed gene-expression and protein-synthesis effects.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Calculation example | 1 mg | See source guide · See source guide | Injectable · 20 mg lyophilized vial + 3 mL BAC Water |
Reference cycle
10-20 days
Reference storage
Injectable: 2-8°C refrigerated
Khavinson Peptide Bioregulators
Short Peptides and Bronchial Function
Bioregulator Peptides and Respiratory Health
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
